Back to Search
ROBERT DIASIO, MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1659568939Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (20)
Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
PMID 19663627·Expert Opin Drug Saf·2009
8-other
Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?
PMID 18326935·JOP·2008
5-case
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
PMID 18245778·Ann Oncol·2008
4-observational
Capecitabine-related cardiotoxicity: recognition and management.
PMID 18257400·J Support Oncol·2008
8-other
Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism.
PMID 18216719·Pharmacogenet Genomics·2008
8-other
Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy.
PMID 17324113·Pharmacogenomics·2007
6-review
Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression.
PMID 17612628·Biochem Cell Biol·2007
8-other
Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation?
PMID 18632519·Support Cancer Ther·2007
8-other
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
PMID 17993734·JOP·2007
5-case
Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.
PMID 18075467·Pharmacogenet Genomics·2007
8-other
Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups.
PMID 17538178·J Clin Oncol·2007
6-review
Hypokalemia secondary to capecitabine: a hidden toxicity?
PMID 18360625·Ther Clin Risk Manag·2007
8-other
The continuum of care: a paradigm for the management of metastatic colorectal cancer.
PMID 17227899·Oncologist·2007
6-review
DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.
PMID 18846242·Pak J Med Sci·2007
8-other
DPYD*2A mutation: the most common mutation associated with DPD deficiency.
PMID 17165084·Cancer Chemother Pharmacol·2007
5-case
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
PMID 16943524·J Clin Oncol·2006
3-trial
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.
PMID 17000684·Clin Cancer Res·2006
4-observational
Peripheral neuropathy exacerbation associated with topical 5-fluorouracil.
PMID 17001184·Anticancer Drugs·2006
5-case
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
PMID 17026792·Clin Colorectal Cancer·2006
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1659568939
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile